Deal facts
- Buyer
- Rosemont Pharmaceuticals Holdings, Inc.
- Target
- Aytu BioPharma Inc.
- Deal value
- Not disclosed
- Announced
- 16 November 2026
- Status
- Firm intention
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
Aytu BioPharma Inc., a Nasdaq-listed Delaware company, agreed on November 16, 2026 to be acquired by Rosemont Pharmaceuticals Holdings, Inc. The two signed an Agreement and Plan of Merger with RoseApollo Merger Sub, Inc., a wholly owned Rosemont subsidiary. The company issued a press release the same day announcing the agreement. Aytu's board and a special committee of the board unanimously recommended that stockholders accept the offer and tender their shares.
The merger agreement sets the price at $2.70 per share, paid in cash without interest and subject to tax withholding. The filing gives only this per-share price and no aggregate deal value. Unvested options become fully vested immediately before the effective time. Options with an exercise price below the offer price are cashed out for the spread, while those at or above it are cancelled for no consideration, after holders get at least ten days to exercise them. Restricted shares are treated as ordinary shares, with certain employee-held shares paid within set payroll timing. The equity plans and the employee stock purchase plan terminate at the effective time.
The structure is a two-step deal. Within ten business days of signing, the purchaser must start a tender offer for all outstanding shares. Unless extended, the offer expires one minute after 11:59 p.m. New York City time on the twentieth day following and including commencement, as calculated under Rule 14d-1(g)(3). Offer conditions include the tender of a majority of outstanding shares, counting shares already owned by Rosemont, the purchaser and their wholly owned subsidiaries. They also include required third-party consents, payoff letters for outstanding debt and a requirement that no more than 15% of the company warrants, measured by underlying shares, remain outstanding without having been exercised before the offer expires. There is no financing condition. Certain officers, all directors and certain stockholders signed tender and support agreements with Rosemont and the purchaser. They agreed to tender all their shares and to terminate their warrants at the effective time for the consideration in those agreements.
After the purchaser accepts tendered shares, the merger is to be completed under Section 251(h) of the Delaware General Corporation Law, without a stockholder meeting or vote. The purchaser merges into Aytu, which survives as a wholly owned Rosemont subsidiary. Aytu has agreed to non-solicitation restrictions and owes Rosemont a $2.4 million termination fee in specified circumstances, including a switch to a superior proposal or an adverse recommendation change. Either side may terminate if the offer is not completed by February 14, 2027, the 90th day after signing. The offer has not yet commenced, and Rosemont will file a Schedule TO and Aytu a Schedule 14D-9 when it does.
Deal timeline
1 update- Firm intention
Rosemont Pharmaceuticals Holdings, Inc. firm intention to acquire Aytu BioPharma Inc.
Item 1.01 Entry into a Material Definitive Agreement. On November 16, 2026, Aytu BioPharma Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Rosemont Pharmaceuticals Holdings, Inc., a Delaware corporation (“Parent”), and RoseApollo Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”). T
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Merck KGaA, Darmstadt, Germany to acquire Rapid Micro Biosystems, Inc.
Merck KGaA, Darmstadt, Germany has agreed to acquire Rapid Micro Biosystems, Inc. (Nasdaq: RPID) for cash. The Agreement and Plan of Merger was signed on November 16, 20…
- Buyer
- Merck KGaA, Darmstadt, Germany
- Target
- Rapid Micro Biosystems, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Merck KGaA, Darmstadt, Germany to acquire Silence Therapeutics plc
Merck KGaA, based in Darmstadt, Germany, has agreed to acquire Silence Therapeutics plc in a cash deal that will take the healthcare company private. The transaction, an…
- Buyer
- Merck KGaA, Darmstadt, Germany
- Target
- Silence Therapeutics plc
- Deal value
- Not disclosed
- Deal type
- going private
ArcheNova Technology Co., Ltd to acquire ArcheNova Biotech Corp.
ArcheNova Technology Co., Ltd has agreed to acquire ArcheNova Biotech Corp. in a transaction valued at two billion US dollars. The deal, announced on 13 October 2026, in…
- Buyer
- ArcheNova Technology Co., Ltd
- Target
- ArcheNova Biotech Corp.
- Deal value
- USD 2,000,000,000
- Deal type
- going private
Onyx Bidco LLC to acquire Option Care Health, Inc.
Option Care Health, Inc. entered into an Agreement and Plan of Merger on October 5, 2026 with Onyx Bidco LLC and its wholly owned subsidiary Onyx Merger Sub, Inc., both…
- Buyer
- Onyx Bidco LLC
- Target
- Option Care Health, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Lifecore Inc. to acquire Lifecore Biomedical, Inc.
Lifecore Inc. and Lifecore Biomedical, Inc. entered the Exit Mode archive.
- Buyer
- Lifecore Inc.
- Target
- Lifecore Biomedical, Inc.
- Deal value
- Not disclosed
- Deal type
- going private
Buyer history
Rosemont Pharmaceuticals Holdings, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive